Olga Kaluzynska
Lodz, LD 92216, Poland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
MMP-9 Serum Levels in Schizophrenic Patients during Treatment Augmentation with Sarcosine (Results of the PULSAR Study).
Journal: International journal of molecular sciences
Published: April 27, 2016
Comparison of Metabolite Concentrations in the Left Dorsolateral Prefrontal Cortex, the Left Frontal White Matter, and the Left Hippocampus in Patients in Stable Schizophrenia Treated with Antipsychotics with or without Antidepressants. ¹H-NMR Spectroscopy Study.
Journal: International journal of molecular sciences
Published: August 07, 2015
No changes of cardiometabolic and body composition parameters after 6-month add-on treatment with sarcosine in patients with schizophrenia.
Journal: Psychiatry research
Published: May 14, 2015
Supplementation of antipsychotic treatment with sarcosine – GlyT1 inhibitor – causes changes of glutamatergic (1)NMR spectroscopy parameters in the left hippocampus in patients with stable schizophrenia.
Journal: Neuroscience letters
Published: May 11, 2015
Adding Sarcosine to Antipsychotic Treatment in Patients with Stable Schizophrenia Changes the Concentrations of Neuronal and Glial Metabolites in the Left Dorsolateral Prefrontal Cortex.
Journal: International journal of molecular sciences
Published: May 01, 2015
Hypomania after augmenting venlafaxine and olanzapine with sarcosine in a patient with schizophrenia: a case study.
Journal: Neuropsychiatric disease and treatment
Published: March 19, 2015
Neurological soft signs as a candidate for endophenotype of schizophrenia
Journal: Psychiatria polska
Published: June 21, 2014
Showing 1-10 of 10
Last Updated: 09/26/2026